SS
TVRD

SBI Securities’s Tvardi Therapeutics TVRD Stock Holding History

SBI Securities’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6 Sell
3
-2
-40% -$6 ﹤0.01% 3973
2026
Q1 		$16 Buy
5
+1
+25% +$4 ﹤0.01% 3800
2025
Q4 		$17 Hold
4
– – ﹤0.01% 3808
2025
Q3 		$156 Hold
4
– – ﹤0.01% 3399
2025
Q2 		$93 Sell
4
-2
-33% -$47 ﹤0.01% 3562
2025
Q1 		$86 Sell
6
-1
-14% -$15 ﹤0.01% 3494
2024
Q4 		$129 Buy
+7
New +$76 ﹤0.01% 3383

Other funds holding TVRD

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

SBI Securities's TVRD Position: Q2 2026 in Review

SBI Securities reduced its Tvardi Therapeutics (TVRD) stake by 40% in Q2 2026, selling an estimated $6 and leaving 3 shares worth $6. The position accounts for ﹤0.01% of the portfolio, ranked #3973.

SBI Securities first reported a position in TVRD in Q4 2024 and has held it in 7 quarters since. The position peaked at $156 in Q3 2025. 58 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • SBI Securities held 3 shares of Tvardi Therapeutics worth $6 as of Q2 2026.
  • SBI Securities sold 2 Tvardi Therapeutics shares in Q2 2026, an estimated $6.
  • Tvardi Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3973 holding.
  • SBI Securities first reported a position in Tvardi Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Tvardi Therapeutics position peaked at $156 in Q3 2025.
  • 58 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.